Human Reproduction: Bioengineering Aspects of Contraception Applied to the Development of a New Female Contraceptive

  • Bruce W. Vorhauer

Abstract

This paper has two purposes: the first is to describe the basic physiology of human reproduction, with particular emphasis on intervention in the reproductive process for the purpose of contraception; the second is to present a new barrier method of contraception for females which has been developed by Vorhauer Laboratories, Inc.

During the design and development of this non-implantable, vaginal contraceptive sponge (VCS) device, the bioengineering aspects of human sexual intercourse and the esthetics of this activity were basic considerations. As a background for the rationale involved, the physiology of the human male and female reproductive systems, the response of human anatomy during coitus, and the fundamentals of current contraceptive techniques are reviewed. Details of the development process are given to provide insight into the medical-bioengineering interfaces involved, and the clinical evaluation programs establishing the safety and effectiveness of the VCS are also outlined.

The COLLATEXTM Contraceptive Sponge developed by VLI is a diaphragm like device, molded from a new biomaterial, a hydrophilic polyurethane. The VCS is impregnated with a conventional spermicide, Nonoxynol-9. Because of its compatibility with the vaginal environment, the device is intended for a single 2-day use period, with multiple coital episodes possible during this time. Sexual spontaneity is thus inherent in the method since no preparations are required for contraception, other than insertion of the sponge (which can be done up to two days prior to intercourse). The VCS can be inserted and removed as desired by the user. In certain lesser developed countries where price is an extreme consideration, the product will undoubtedly be washed and reused, although this is not recommended since the spermicide can be depleted by repeated washings. Because of its material compliance, the VCS adapts to anatomical variations which are a function of the user and her daily activities. Currently, one size of the sponge is intended for all users.

Appropriate regulatory compliance filings have been made with the United States FDA, and the VCS is currently undergoing extensive clinical effectiveness evaluations. Once marketing approval has been obtained, the product will be sold as an over-the-counter (OTC) contraceptive. Initial marketing of the product outside the United States is scheduled for late 1980.

Keywords

None None Collagen Sponge Vaginal Tablet Polyurethane Sponge Vaginal Distention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Million Teenagers“, a pub. of the Alan Guttmacher Institute, 515 Madison Ave., New York, 1976.Google Scholar
  2. [2]
    Fertility and Contraception in the United States, Report prepared by the Select Committee on Population, U.S. House of Representatives, 95th Congress, 2nd Session, 12/78.Google Scholar
  3. [3]
    Blandau, R. & Moghissi, K., ed., The Biology of the Cervix, University of Chicago Press, Chicago, 1973.Google Scholar
  4. [4]
    Epel, David, “The Program of Fertilization”, Sci. Am., 11/77, pp. 129–138.Google Scholar
  5. [5]
    Garcia, G. R. & Rosenfeld, D. L., Human Fertility: The Regulation of Reproduction, F. A. Davis Co., Phil., 1977.Google Scholar
  6. [6]
    Hafez, E. S. F. & Evans, T. N., editors, Human Reproduction, Conception and Contraception, Harper & Row, Hagerstown, MD., 1973.Google Scholar
  7. [7]
    Masters, W. H. & Johnson, V. E., Human Sexual Response, Little, Brown & Co., Boston, 1966.Google Scholar
  8. [8]
    Segal, S. J., “The Physiology of Human Reproduction”, Sci. Am., 9/74, pp. 53–62.Google Scholar
  9. [9]
    Taylor, H., ed., Human Reproduction, Vol. 1, Physiology, MIT Press, Cambridge, 1976.Google Scholar
  10. [10]
    Johnson, V. E. & Masters, W. H., “Intravaginal Contraceptives Study: Phase I. Anatomy”, Western J. Surg. Obstet. Gynecol., 7–8/62, p. 202.Google Scholar
  11. [11]
    Shapiro, H. I., The Birth Control Book, St. Martin’s Press, New York, 1977.Google Scholar
  12. [12]
    Hatcher, R. A., et al, Contraceptive Technology, 1978–1979, John Wiley, Irvington Publishers, N.Y., 1978.Google Scholar
  13. [13]
    Population Report, Series A, #1–5, 9/75, Population Information Program, The Johns Hopkins Univ., 624 N. Broadway, Baltimore, 21205.Google Scholar
  14. [14]
    Ibid, Series B, #2–3, 1/75.Google Scholar
  15. [15]
    Ibid, Series H, #1–5, 1/76.Google Scholar
  16. [16]
    Ibid, Series D, #1–3, 1/75.Google Scholar
  17. [17]
    Bender, S. J. & Fellers, S., Contraception, by Choice or by Chance, WM. C. Brawn Co., Dubuque, Io., 1971Google Scholar
  18. [18]
    Segal, S. J., “Advances and Opportunities in Fertility Research”, Mt. Sinai J. of Med., Vol XLII, #4, 7–8/75, pp. 375–383.Google Scholar
  19. [19]
    Hines, N. E., Medical History of Contraception, Schocken Books, N.Y., paperback, 1970.Google Scholar
  20. [20]
    Bernstein, E., “Update on the Pill: Does Reliability Outweigh Risk?”, Today’s Health, 3/76, p. 15.Google Scholar
  21. [21]
    FDA Drug Bulletin, “Risk of Myocardial Infarction in Users of Oral Contraceptives”, 7–8/75, p. 10.Google Scholar
  22. [22]
    Morrison, M., “Contraception with IUD’s”, FDA Consumer, 2/75, DHEW Pub. #75–4005.Google Scholar
  23. [23]
    Bernstein, G. S., “Physiological Aspects of Vaginal Contraception, A Review”, Contraception, Vol. 9, #4, 4/74, pp. 333–345.Google Scholar
  24. [24]
    Bernstein, G. S., “Coventional Methods of Contraception: Condom, Diaphragm, and Vaginal Foam”, Clin. Ob. Gyn,,Vol. 17, #1, 3/74, pp. 21–33.Google Scholar
  25. [25]
    Patent applications filed U.S. and foreign by VORHAUER LABORATORIES, INC.Google Scholar
  26. [26]
    Hypol 2001 Prepolymer, W. R. Grace and Co., Organic Chemicals Div., Lexington, NA.Google Scholar
  27. [27]
    Aznar, et. al., “Polyurethane Contraceptive Sponge: Product Modification Resulting from User Experience”, submitted to Contraception, 1980.Google Scholar
  28. [28]
    Wallin, R., “Safety Testing of Medical Devices, an Overview”, Ned. Dev. & Diag. Indust., Vol. 1, #6, 11/79, p. 25.Google Scholar
  29. [29]
    Chvapil, M., Personal CamnnZication to B. W. Vorhauer, 10/27/76.Google Scholar
  30. Moran, J., et. al., “Comparison of the Fractional Post-coital Test with the Sims-Huhner Post-coital Test”, Int. J. Fertility, Vol. 19, 1974, p. 93.Google Scholar
  31. [31]
    Bernstein, G. S., “Laboratory Studies of the Release of Nonoxynol-9 from Polymeric Intravaginal Contraceptive Sponges”, submitted to Contraception, 1979.Google Scholar
  32. [32]
    Bernstein, G. S., et. al., paper in preparation for submission to Contraception, 1980.Google Scholar
  33. [33]
    Aznar, et. al., “A Clinical Appraisal of a Medicated Polyurethane Sponge Used for Contraception”, in Vaginal Contraceptives: New Developments, Zatuchni, G., et. al., editors, Harper and Row, Hagerstown, in Press.Google Scholar
  34. [34]
    Taylor, R., et. al., “Preliminary Results of a Multi-clinic Trial of a Polyurethane-Spermicide Contraceptive Sponge”, ibid.Google Scholar
  35. [35]
    Edelman, D. A., “Barrier Contraception - An Update”, presented at the Assoc. of Family Planning Physicians Meeting in Philadelphia, 10/79., and to be published in Advances in Planned Parenthood, 1980.Google Scholar
  36. [36]
    Biomedical Engineering Axiom No. 1 - Under carefully controlled experimental conditions, organisms behave pretty much as they please.Google Scholar

Copyright information

© Springer Science+Business Media New York 1980

Authors and Affiliations

  • Bruce W. Vorhauer
    • 1
  1. 1.Vorhauer Laboratories, Inc.Costa MesaUSA

Personalised recommendations